The treatment of angelic syndrome ushers in a new breakthrough! FDA Grants OV101 Orphan Drug Title

Angel icing syndrome is a disease caused by a genetic defectChildren with the disease often have a smile on their face, lack of language skills, hyperactivity, and low intelligenceAbout 80% of patients haveepilepsysymptoms, about 50% have microcephalyThe cause of angelic syndrome is a defect in the 15q part of the imprinting gene region of chromosome 15 from the mother, or two chromosome 15s from the father with this defectangelic syndrome is associated with a decrease in the effect of strong straightening inhibition, a function of selective GABAareceptor, which enables the human brain to correctlyinterpretation ofexcitability and inhibition nerve signalsBiopharmaceutical company Ovid Therapeutics recently announced that the U.SFDAhas awarded OV101 (gaboxadol) orphan drug title to treat angel icing syndromeOV101 is considered to be the only selective GABAa receptor agonist under development and is currently undergoing a critical Phase III NEPTUNE trial, the main results of which are expected to be announced in the fourth quarter of 2020 "OV101 has the potential to become the first FDA-approved treatment for angelic human syndrome," said Amit Rakhit, M.D., President and Chief Medical Officer of Ovid Therapeutics Getting the orphan drug designation from the FDA is an important milestone for Ovid With this designation, we are eligible for FDA priority review rights."